Benefits
Improved Blood Flow
L-arginine may enhance circulation, potentially benefiting conditions like high blood pressure, erectile dysfunction, and peripheral artery disease. Studies suggest modest improvements in blood pressure and exercise capacity in some populations.
Heart Health
It may reduce symptoms of angina and improve vascular function, though evidence is mixed and not conclusive for preventing heart disease.
Erectile Dysfunction
Some research indicates L-arginine, especially when combined with supplements like pycnogenol, can improve mild to moderate erectile dysfunction by enhancing blood flow.
Exercise Performance
Limited evidence suggests it may boost exercise tolerance, particularly in untrained individuals or those with cardiovascular issues, but results vary.
Wound Healing
L-arginine may support tissue repair and immune function, potentially aiding recovery in burn patients or those with chronic wounds.
Immune Support
It may enhance immune response, particularly in specific medical contexts, but more research is needed.
Mechanism of action
Nitric Oxide Synthesis
L-arginine is converted into nitric oxide by the enzyme nitric oxide synthase (NOS) in endothelial cells, macrophages, and other tissues. This reaction also produces L-citrulline as a byproduct. Nitric oxide acts as a vasodilator, relaxing smooth muscle cells in blood vessel walls, which improves blood flow and reduces vascular resistance.
Vascular Effects
By increasing NO levels, L-arginine promotes vasodilation, which enhances blood circulation, lowers blood pressure, and improves oxygen delivery to tissues. This is particularly relevant in conditions like hypertension, erectile dysfunction, or atherosclerosis, where impaired NO production is a factor.
Cellular and Metabolic Role
L-arginine supports protein synthesis and serves as a building block for proteins, aiding tissue repair and growth. It stimulates the release of hormones like insulin and growth hormone, which may enhance metabolism and tissue recovery. In immune cells, L-arginine supports the production of NO, which has antimicrobial properties and modulates immune responses.
Clinical trials
Randomized, double-blind, placebo-controlled trial in 101 patients with severe COVID-19 receiving L-arginine 1.66 g twice daily plus standard therapy vs standard therapy alone. (Fiorentino et al. 2021, EClinicalMedicine)
101 severe COVID-19 patients.
L-arginine reduced respiratory support duration and length of hospitalization vs control. Modest effect; should not be considered established COVID-19 treatment but suggests metabolic support utility in critical illness.
Double-blind, randomized, placebo-controlled trial in 98 patients (51 L-arginine 6 g/day, 47 placebo) with vasculogenic erectile dysfunction for 3 months. (2021)
98 men with vasculogenic ED.
L-arginine modestly improved IIEF-5 (International Index of Erectile Function) scores vs placebo. Critical context: PDE5 inhibitors (sildenafil, tadalafil) remain first-line for ED; arginine effects are smaller in magnitude; arginine may have niche role for mild ED or as adjunct in patients on standard therapy. L-citrulline produces higher arginine levels than equivalent doses of L-arginine itself (better oral bioavailability).
Double-blind, randomized, placebo-controlled trial in 56 healthy male athletes in Iran aged 16-35 receiving L-arginine vs placebo. Outcomes: cardiovascular risk factors, exercise performance.
56 healthy male athletes.
Modest improvements in some cardiovascular risk markers. Note: effects in healthy young athletes typically much smaller than in clinically vulnerable populations. Arginine performance evidence is mixed and effect sizes generally small.
Prospective, open-label, single-arm trial in 20 amyotrophic lateral sclerosis (ALS) patients (40% female, mean age 60.5). Outcomes: ALSFRS-R, FVC, biomarkers.
20 ALS patients (single-arm, no placebo).
Trial reports modest signals of disease stabilization. Critical caveat: open-label single-arm — cannot be considered evidence of efficacy without placebo control. ALS treatment landscape includes riluzole, edaravone (and now tofersen for SOD1-ALS) — supplemental arginine has no role in evidence-based ALS care.
Meta-analysis of 22 randomized, placebo-controlled trials (30 effect sizes) examining oral L-arginine effects on blood pressure. (2022)
Pooled across 22 RCTs.
L-arginine modestly reduced systolic BP (~5.4 mmHg) and diastolic BP (~2.7 mmHg) vs placebo. Effects more pronounced at higher doses (≥4 g/day) and longer durations (≥4 weeks). Mechanism via NO-mediated vasodilation. Note: should not replace antihypertensive medications in established hypertension — adjunctive only.
Multicenter, randomized, double-blind, placebo-controlled trial (Vascular Interaction with Age in Myocardial Infarction — VINTAGE MI) in 153 post-STEMI patients receiving L-arginine 9 g/day vs placebo for 6 months. (Schulman et al. 2006, JAMA)
153 post-STEMI patients. 6-month intervention.
Primary endpoint negative: L-arginine did not improve vascular stiffness or LV ejection fraction vs placebo. Critical safety concern: L-arginine group had 6 deaths vs 0 in placebo group — an alarming and statistically significant signal that led to trial termination for harm. This is a major negative trial that has shaped clinical thinking — high-dose L-arginine should not be used in post-MI patients.
Randomized, double-blind, placebo-controlled crossover trial in 15 patients with moderate to severe heart failure receiving 5.6-12.6 g/day L-arginine vs placebo. (Bednarz et al. 1996, Circulation)
15 heart failure patients (small).
L-arginine modestly improved exercise tolerance and forearm vasodilation vs placebo. Older positive trial — but in light of the VINTAGE MI death signal and lack of large definitive HF trials, L-arginine is not recommended in standard HF care. Modern HF therapy (ACEi/ARB/ARNI, beta-blocker, MRA, SGLT2i) has clear mortality evidence.